ThinkSabio

$ABBV

$274.10▲ -2.4% YTD

17 SEC 13D/G filings tracked · Last updated Oct 13, 2026

Filing History
News
ABBV ▼ -2.4% - AbbVie Inc.
CP $274.10▲ -2.4%Oct 13, 2026 · ThinkSabio Blog

$ABBV - AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients Wi…

News
ABBV ▲ +1.5% - AbbVie Inc.
CP $276.47▲ +1.5%Oct 11, 2026 · ThinkSabio Blog

$ABBV - New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disea…

News
ABBV ▲ +0.6% - AbbVie Inc.
CP $268.31▲ +0.6%Oct 7, 2026 · ThinkSabio Blog

$ABBV - AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC…

News
ABBV ▲ +0.6% - AbbVie Inc.
CP $264.75▲ +0.6%Oct 5, 2026 · ThinkSabio Blog

$ABBV - Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survi…

News
ABBV ▼ -0.1% - AbbVie Inc.
CP $261.61▲ -0.1%Oct 1, 2026 · ThinkSabio Blog

$ABBV - AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo…

News
ABBV ▼ -0.0% - AbbVie Inc.
CP $261.80▲ -0.0%Oct 1, 2026 · ThinkSabio Blog

$ABBV - AbbVie to Host Third-Quarter 2026 Earnings Conference Call…

News
ABBV ▼ -1.2% - AbbVie Inc.
CP $263.29▲ -1.2%Sep 30, 2026 · ThinkSabio Blog

$ABBV - AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Break…

News
ABBV ▼ -1.2% - AbbVie Inc.
CP $263.29▲ -1.2%Sep 30, 2026 · ThinkSabio Blog

$ABBV - AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EAD…

News
ABBV ▼ -0.2% - AbbVie Inc.
CP $264.04▲ -0.2%Sep 22, 2026 · ThinkSabio Blog

$ABBV - Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach…

News
ABBV ▲ +0.5% - AbbVie Inc.
CP $265.05▲ +0.5%Sep 22, 2026 · ThinkSabio Blog

$ABBV - AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiop…

News
ABBV ▼ -0.7% - AbbVie Inc.
CP $261.90▲ -0.7%Sep 21, 2026 · ThinkSabio Blog

$ABBV - AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery…

News
ABBV ▲ +0.0% - AbbVie Inc.
CP $261.77▲ +0.0%Sep 15, 2026 · ThinkSabio Blog

$ABBV - AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign…

News
ABBV ▲ +0.9% - AbbVie Inc.
CP $253.18▲ +0.9%Sep 10, 2026 · ThinkSabio Blog

$ABBV - AbbVie Declares Quarterly Dividend…

News
ABBV ▲ +0.4% - AbbVie Inc.
CP $252.09▲ +0.4%Sep 10, 2026 · ThinkSabio Blog

$ABBV - AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine…

News
ABBV ▲ +0.3% - AbbVie Inc.
CP $262.44▲ +0.3%Sep 3, 2026 · ThinkSabio Blog

$ABBV - AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progressio…

News
ABBV ▲ +0.3% - AbbVie Inc.
CP $262.44▲ +0.3%Sep 3, 2026 · ThinkSabio Blog

$ABBV APGE - AbbVie Completes Acquisition of Apogee Therapeutics…

News
ABBV ▲ +0.8% - AbbVie Inc.
CP $261.90▲ +0.8%Sep 2, 2026 · ThinkSabio Blog

$ABBV - Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care…